Similarly, studies regarding the association between radiomic features and the PFS of patients with ALK-rearranged NSCLC were limited to advanced-stage tumors treated with ALK-TKIs (Li et al., 2020; Hou et al., 2023; Sun et al., 2023), and also showed the significant prognostic performance of the radiomics signature. The gene discussed is ALK; the disease is non-small cell lung carcinoma.